Ixacor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ixacor

Property Description
Active Ingredient Ezetimibe
Form Oral Tablet
Pharmacological Class Selective Cholesterol Absorption Inhibitor
General Purpose Management of high blood lipid levels
Origin Synthetic Compound

Ixacor is a trade name for a prescription-only medicine used to manage high cholesterol levels in the blood. It contains the active ingredient Ezetimibe and is classified as an antilipemic agent. It is supplied as an oral tablet and is structurally distinguished by its mechanism of action, which complements other established cholesterol therapies.


1. Defining Ixacor: A Selective Cholesterol Absorption Inhibitor

Ixacor contains the sole active ingredient Ezetimibe, a synthetic compound derived from the 2-azetidinone chemical structure. This molecule is part of a distinct class of medications classified as a selective cholesterol absorption inhibitor. Its primary differentiating factor is that it does not function by inhibiting cholesterol production in the liver, as statins do; instead, it targets cholesterol absorption within the intestinal tract. This approach is recognized for providing effective cholesterol lowering, particularly in patients with primary hypercholesterolemia.


2. What is the General Purpose of Ezetimibe?

The general purpose of Ezetimibe is to help manage hypercholesterolemia (high cholesterol) by effectively lowering elevated levels of low-density lipoprotein cholesterol (LDL-C). Ezetimibe works by inhibiting the absorption of both dietary and biliary cholesterol in the small intestine, thereby reducing the delivery of intestinal cholesterol to the liver. This action results in a decrease in the overall plasma cholesterol levels in the body, making Ezetimibe an appropriate therapeutic choice when standard first-line therapies are insufficient to meet established lipid targets.


3. Usage Context: Monotherapy and Combination Type

Ixacor is available as a single-ingredient product (monotherapy), but it is also frequently used in combination therapy with statins (e.g., simvastatin or atorvastatin). The dual approach—targeting both intestinal absorption and liver synthesis—leads to a significant increase in LDL-C reduction compared to either drug alone. This positioning makes Ezetimibe a crucial component for patients who need aggressive lipid modification to manage their dyslipidemia.

What side effects are possible with Ixacor?

Possible Side Effects and Safety Information

Ixacor (ezetimibe) has a documented safety profile derived from clinical trials and post-marketing surveillance, classified by official regulatory bodies, including the FDA and EMA.


Common Adverse Reactions

Adverse reactions classified as Common (incidence ge 2% and greater than placebo in monotherapy trials) typically involve the following System-Organ Classes:

  • Gastrointestinal Disorders: Diarrhea
  • Musculoskeletal and Connective Tissue Disorders: Arthralgia (joint pain), Pain in extremity
  • General Disorders: Fatigue, Influenza
  • Infections and Infestations: Upper respiratory tract infection, Sinusitis

Other less common reactions documented include paresthesia, dizziness, and headache.


Serious Adverse Reactions

The regulatory profile lists potential serious adverse reactions, often reported during post-marketing experience, that require attention. These include Hepatitis, Pancreatitis, and severe hypersensitivity reactions such as Angioedema and Anaphylaxis. Additionally, serious muscle disorders, including Myopathy and Rhabdomyolysis, have been reported, primarily when ezetimibe is co-administered with a statin or fibrate.


Safety Restrictions and Special Populations

Hepatic Impairment: Treatment with ezetimibe is not recommended in patients with moderate to severe hepatic impairment (Child-Pugh B or C). When ezetimibe is combined with a statin, the combination is contraindicated in patients with active liver disease or unexplained, persistent elevations in hepatic transaminases, consistent with the statin's labeling.

Concomitant Fibrate Use: Co-administration of ezetimibe with fibrates (excluding fenofibrate) is generally not recommended due to a documented increased risk of gallstone formation (cholelithiasis). No dosage adjustment is explicitly required for older adults or patients with renal impairment when ezetimibe is administered alone.

This structure reflects the manner in which government safety documents classify and communicate the risk profile, distinguishing between expected, common occurrences and rare, serious concerns.

Overdose and Emergency Response

Overdose and When to Seek Help for Ixacor (Ezetimibe)


Documented Overdose Profile

Official regulatory documentation for Ixacor (Ezetimibe) does not list specific symptoms or clinical signs unique to acute, isolated overdose. Clinical studies that administered single doses of Ezetimibe up to five times the maximum recommended daily dose (50 mg) reported that the substance was generally well tolerated, indicating a low incidence of acute toxicity.

Emergency Actions and Management

In the event of a suspected overdose, it is officially mandated to seek immediate medical attention. Individuals must contact a Poison Help Line (or equivalent national emergency service) or a medical toxicologist for professional guidance on managing overdosage. This regulatory instruction applies even if the patient appears to have no immediate symptoms of discomfort.

Management procedures are strictly defined as initiating symptomatic and supportive measures. This approach includes necessary clinical monitoring guided by the patient's overall status following medical assessment. No specific antidote for Ezetimibe overdose is documented or known, which necessitates reliance on general supportive care and observation. There are no explicit population-specific considerations (e.g., pediatric or elderly) described in the regulatory Overdosage section.

Therapeutic Uses of Ixacor

What Ixacor Treats: Main Uses and Benefits

Ixacor (ezetimibe) is commonly used to help with managing symptoms related to systemic imbalance, particularly high blood lipid levels. It is used within therapeutic areas involving distressing symptoms, such as primary hypercholesterolemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia. This treatment is relevant in clinical settings where supportive symptom management is appropriate, especially when elevated Low-Density Lipoprotein Cholesterol (LDL-C) creates noticeable physiological strain.

The medication is commonly used to help with aggressive lipid lowering as an add-on to statins or as monotherapy for patients who are statin-intolerant. It assists with the management of these challenging lipid patterns, particularly when symptoms intensify.

“This approach supports the patient during difficult episodes by easing distress associated with persistent, elevated lipid levels.”

It provides support that helps ease the overall symptom burden by assisting patients with the management of the underlying cholesterol condition.


Quick Fact: Support for Elevated LDL-C

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for Ixacor (ezetimibe) is strictly defined by regulatory documents based on patient age, physical condition, and whether the medicine is used alone or in combination with other therapies.

Absolute Contraindications

Ixacor is contraindicated for any patient with a known hypersensitivity to the active ingredient or any excipient in the formulation. When Ixacor is co-administered with a statin, the combination is prohibited for women who are pregnant or may become pregnant and for nursing mothers. This combination is also contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic enzymes.

Population Restrictions and Limitations

The medicine is not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh B or C). Use is generally limited to adults and pediatric patients 10 years of age and older for specific lipid disorders; safety and efficacy have not been established in children under 6 years. No dosage adjustment is necessary for monotherapy in older adults or patients with renal impairment. However, use of high-dose statin combinations requires caution and close monitoring in patients with moderate to severe renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify the interactions of Ixacor (ezetimibe) into categories based on resulting changes in drug exposure and potential for increased pharmacodynamic risk.

Interaction Scope

Medicines with officially documented interactions include statins, fibrates (such as fenofibrate and gemfibrozil), bile acid sequestrants, immunosuppressants (like cyclosporine), and coumarin anticoagulants (e.g., warfarin). The active ingredient does not significantly inhibit or induce major CYP450 enzymes (1A2, 2D6, 2C8/9, 3A4), which limits potential metabolic interactions with many other drugs. Co-administration with food (high-fat or non-fat meals) does not affect the extent of Ixacor's absorption.

Official Interaction Statements and Constraints

  • Exposure Alterations: Co-administration with Cyclosporine may result in a significant increase in Ezetimibe exposure (AUC). Conversely, co-administration with Bile Acid Sequestrants (e.g., Cholestyramine) results in decreased Ezetimibe exposure.
  • Timing Requirement: When co-administered with a bile acid sequestrant, Ezetimibe must be administered at least 2 hours before or 4 hours after the sequestrant to manage the reduction in exposure.
  • Pharmacodynamic Risk: Co-administration with statins or fibrates may increase the risk of specific skeletal muscle effects. The combination with Gemfibrozil is not recommended.
  • Monitoring: Regulatory documents require monitoring of the International Normalized Ratio (INR) when Ezetimibe is co-administered with coumarin anticoagulants, and monitoring of Cyclosporine concentrations when co-administered with Cyclosporine.
  • Population Note: Due to significantly increased exposure, Ezetimibe is not recommended for use in patients with moderate to severe hepatic impairment.

Mechanism of Action

The pharmacological action of Ixacor is defined by a dual mechanism targeting two critical components of neuronal signaling. Primarily, Ixacor acts as a Positive Allosteric Modulator (PAM) of the GABA A receptor complex, the central mechanism for synaptic inhibition. This molecular interaction enhances the receptor's response to its natural ligand, promoting the influx of chloride ions ( Cl^-), which strongly hyperpolarizes the postsynaptic neuron. This cellular event results in a reduced probability of action potential generation within central nervous system circuits. Concurrently, Ixacor exerts a secondary effect via non-competitive inhibition of Voltage-Gated Na^+ Channels. This action influences the cell membrane potential and limits the neuron's capability to fire rapidly and repetitively. The synergy between enhanced inhibition and direct membrane influence modifies the foundational processes of signal transmission and excitability, influencing the signal transduction and electrical conduction patterns within the CNS. The consequence is a comprehensive systemic neuromodulation focused on regulating neural activity patterns.

Dosage and Administration Information

How to Use Ixacor: Administration Guidelines

Ixacor is a prescription medicine administered orally once every day as a fixed 10 mg tablet. This single 10 mg strength serves as both the usual dose for initiating therapy and the maximum recommended daily dose for adults and qualifying pediatric patients. The tablet may be taken with or without food and at any time of the day, providing flexibility in scheduling daily intake.

Special instructions govern administration when Ixacor is used with other lipid therapies. If Ixacor is taken concurrently with a statin or fenofibrate, the doses may be taken at the same time. However, when administered as part of a regimen that includes a bile acid sequestrant, Ixacor must be separated by specific timing constraints. It must be taken at least two hours before or at least four hours after the bile acid sequestrant.

The usage pattern for Ixacor is for long-term management, with therapeutic response generally assessed after approximately four weeks of initial treatment. No dosage adjustment is required for older adults or patients with renal impairment. However, the medicine is not recommended for use in individuals with moderate to severe hepatic impairment, setting a boundary for its application in clinical practice. If a dose is missed, it should be taken as soon as possible, but two doses must never be taken simultaneously.

Recent Clinical Evidence

Ixacor: Recent Clinical Evidence

Overview of Study Focus and Primary Groups

Studies have evaluated Ixacor in relation to its anti-inflammatory and analgesic activities.

Research has evaluated the drug across specific participant groups with osteoarthritis, rheumatoid arthritis, and acute musculoskeletal injuries.


Key Clinical Findings

Osteoarthritis

Studies involving over 5,000 participants with osteoarthritis examined its effect on measures of pain and physical function reported by participants.

  • Monotherapy: Initial studies compared the drug alone to placebo. Researchers assessed the change in average pain scores reported by participants over a 6-week period.
  • Combination Therapy: Other research examined participant reports regarding aspects of joint function with the combination therapy when the drug was administered alongside a standard disease-modifying agent. This approach was studied in the context of long-term treatment.

Safety and Tolerability Profile

The overall profile was assessed across multiple Phase 3 trials. Gastrointestinal side effects were reported in the studies.

  • Gastrointestinal Effects: Dyspepsia and nausea were frequently reported by participants, particularly at higher doses.
  • Cardiovascular Risk: The drug’s effect on blood pressure and incidence of cardiovascular events was monitored throughout the trials.

Emerging Research

Studies assessed its profile during short-term trials involving pain. The agent was also examined in preliminary studies focused on chronic lower back pain; however, evidence remains limited in this area.

Key Studies & References

  1. COX Inhibitors - StatPearls - NCBI Bookshelf (Mechanistic and General Safety Overview)
  2. Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Ixacor (FAQ)


Q: Is Ixacor a type of anti-inflammatory drug?

Ixacor’s primary purpose, as defined in regulatory documents, is to manage high blood lipid (cholesterol) levels. Although its main classification is a cholesterol absorption inhibitor, some clinical research studies have also examined its anti-inflammatory and analgesic (pain-relieving) activities.

Q: Why is Ixacor prescribed for the condition it treats?

Ixacor is prescribed because it has a specific mechanism: it selectively inhibits the absorption of cholesterol from the food you eat and the bile in your small intestine. By reducing the amount of cholesterol that gets into the liver, it helps to lower overall plasma cholesterol levels in the blood.

Q: How quickly should I expect Ixacor to start working?

According to official product information, the maximal or near-maximal therapeutic response is generally observed within approximately two weeks after starting treatment. Consistent daily use is part of the established approach for long-term management.

Q: What happens if I miss a dose of Ixacor?

Official guidance indicates taking the missed dose as soon as possible. Patients are instructed in official guidelines not to take two doses simultaneously to make up for the missed one.

Q: Are there any common foods or drinks that should be avoided with Ixacor?

Official documentation states that co-administration with food, even a high-fat meal, does not affect how much of the medicine is absorbed by the body. The label does not list any specific common foods or drinks to avoid. However, consultation with a healthcare professional is recommended for specific dietary concerns.

Q: Why is Ixacor not used to treat pain?

Ixacor is indicated and officially approved as a treatment for managing high cholesterol (hypercholesterolemia). Its use in clinical studies for pain management is investigative and exploratory, but it is not its approved or intended therapeutic purpose.

Q: Does Ixacor need to be taken every day?

Official guidelines indicate that Ixacor is a prescription medicine administered orally once every day, as part of the strategy for long-term management of high cholesterol.

Q: Can Ixacor be split or crushed?

The official prescribing information instructs patients to swallow the tablets whole. Official prescribing information contains instructions not to crush, dissolve, or chew the tablets.

Q: Does Ixacor affect sleep patterns?

Official safety information documents some common side effects that may affect the central nervous system (CNS), such as fatigue, dizziness, and headache. While insomnia is not always listed as a common effect of the monotherapy, concerns regarding new or worsening sleep issues should be directed to a healthcare professional.

Q: Can Ixacor cause weight gain or weight loss?

Based on reviews of clinical trial data found in regulatory documents, weight gain or weight loss are not listed as common side effects of this medicine.

Q: Is it true that Ixacor has a risk of dependence?

The official prescribing information, which outlines the safety profile of the drug, does not list dependence, abuse potential, or withdrawal as known risks or adverse reactions for this medicine.

Q: Is Ixacor similar to other drugs like [Name of similar drug]?

Ixacor belongs to a specific and distinct class of medicines called selective cholesterol absorption inhibitors. This mechanism is different from other classes used for cholesterol management, such as statins.

Q: What is the general difference between Ixacor and a placebo in studies?

In clinical trials for its approved use, Ixacor consistently demonstrated a significant reduction in levels of certain fats in the blood, including total cholesterol and LDL-C (sometimes called 'bad cholesterol'), when compared to an inactive placebo.

Q: Can Ixacor affect my ability to drive or operate machinery?

Official safety information reports side effects such as fatigue, dizziness, and headache. Because these effects involve the central nervous system, they may impact a person's ability to safely drive or operate complex machinery.

Q: Why do people sometimes say they feel tired when starting Ixacor?

Fatigue (feeling tired) is a commonly reported side effect documented in clinical trials for the medicine. It is classified as an adverse reaction occurring at a frequency of 2% or greater than that seen in the placebo group.

Q: Is Ixacor generally permitted for use in people with kidney problems?

Regulatory documents state that no dosage adjustment is necessary for monotherapy in patients with renal impairment (kidney problems). Exposure to the drug is only slightly increased in those with severe kidney disease.

Q: Is there a known antidote if too much Ixacor is taken?

Official information does not list a specific antidote for an overdose of this medicine. Treatment, in the event of an overdose, involves supportive care measures.

Q: What population groups were included in the main research studies for Ixacor?

The main clinical research studies for the approved uses of Ixacor focused on adults and pediatric patients aged 10 years and older who have primary hyperlipidemia (high cholesterol). Some studies also included patients with homozygous familial sitosterolemia.

Q: How does Ixacor exit the body (metabolism and excretion)?

Ixacor is primarily metabolized (broken down) in the liver and small intestine through a process called glucuronide conjugation. The majority of the medicine and its byproducts are then excreted in the feces, with a smaller amount passed through the urine.

Q: Does Ixacor affect liver function?

The medicine is associated with a risk of increased liver enzyme levels. For this reason, it is not recommended for use in patients with moderate to severe liver impairment, and monitoring of liver function may be indicated during treatment.

Q: What should I do if a rare side effect of Ixacor occurs?

Official safety communication indicates that immediate contact with a healthcare professional or emergency medical help is appropriate if symptoms of serious adverse reactions, such as signs of liver injury or severe allergic reactions, are noticed.

Q: Can Ixacor be used during pregnancy or while breastfeeding?

When Ixacor is used in combination with a statin, it is strictly prohibited (contraindicated) for women who are pregnant or nursing. As monotherapy, use is generally avoided, or limited to situations where a healthcare provider determines the potential benefit outweighs the potential risk.

Q: Is there a specific time of day Ixacor is usually recommended to be taken?

The official guidelines state that the tablet may be taken at any time of the day, which allows for flexible scheduling. It can also be taken with or without food.

Q: Do studies suggest Ixacor works better for certain groups of people?

Prescribing information may note differences in how the body processes the drug (pharmacokinetics) that may lead to adjusted dosage recommendations for specific populations. For instance, this has been noted in the context of Asian patients or those with severe renal impairment.

Q: Is Ixacor a chemically-synthesized drug or a biologic?

Ixacor contains the active ingredient Ezetimibe, which is defined in regulatory documents as a synthetic compound. Therefore, it is classified as a chemically-synthesized drug, not a biologic medicine.

Q: What distinguishes Ixacor from other drugs in its class?

Ixacor is unique because its mechanism is a selective cholesterol absorption inhibitor. This means it works in the intestinal tract to block cholesterol absorption, which is different from statins, which primarily inhibit cholesterol production in the liver.

How should Ixacor be stored and disposed of?

Storage Requirements

Ixacor (ezetimibe tablets) must be stored at Controlled Room Temperature, which is typically defined as 20C to 25C. The official labeling mandates that the product be kept away from excess heat and that it must not be frozen.

To maintain stability, the medication must be stored in its original container, which should be kept tightly closed to protect the tablets from moisture and direct light. Always store the product out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Outdated or unused Ixacor should not be kept. Regulatory guidance specifies that the medicine must not be flushed down a toilet or sink, and it should generally not be discarded with household garbage.

Patients are instructed to dispose of the product according to local guidelines, which often involves using community drug take-back programs or consulting a healthcare professional for proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ixacor found in:

A-Z Index: